Sprint Bioscience: Collaborates to expand its MASH inflammation programme
23 juni, 08:25
23 juni, 08:25
Sprint Bioscience has entered a research collaboration with the Experimental Drug Development Centre (EDDC) in Singapore regarding the therapeutic expansion of Sprint Bioscience’s MASH (metabolic dysfunction-associated steatohepatitis) programme based on STK25 into inflammatory diseases.
23 juni, 08:25
Sprint Bioscience has entered a research collaboration with the Experimental Drug Development Centre (EDDC) in Singapore regarding the therapeutic expansion of Sprint Bioscience’s MASH (metabolic dysfunction-associated steatohepatitis) programme based on STK25 into inflammatory diseases.
Aktierekommendationer
Oljepriset
Aktierekommendationer
Oljepriset
1 DAG %
Senast
Swedbank Robur Global Emerging Markets A
Igår, 15:13
Förvaltaren gör comeback i Japanfonden – Barnevik lämnar
VEF
Igår, 14:01
VEF: Det hänger på Creditas
OMX Stockholm 30
1 DAG %
Senast
2 452,44